Phenomenex and USP Offer Workshop on Practical Application of Chapter <621>
News Feb 15, 2010
Phenomenex Inc., a global leader in the manufacture of separation science consumables, announces that it will be teaching a half-day course in conjunction with USP (U.S. Pharmacopeia) Professional Education on the practical application of Chapter <621> to improve HPLC method stability and speed. The course will be offered each day of Pittcon in Room SR-49 at the Orange County Convention Center in Orlando. The fee of $395 ($495 after February 19) includes conferee registration to Pittcon, course materials and refreshments. Course dates and times are:
Monday, March 1 1:00 – 5:00 p.m.
Tuesday, March 2 8:30 – 12:30 p.m.
Wednesday, March 3 1:00 – 5:00 p.m.
Thursday, March 4 8:30 – 12:30 p.m.
USP Chapter <621> defines the adjustments that labs may make to their LC methods without having to revalidate. The course, taught by top technical managers from Phenomenex and senior USP scientists, will use a combination of lecture and small group exercises to teach ways to adjust HPLC methods in various situations while adhering to the Chapter <621> guidelines. The course will be valuable for lab mangers, bench chemists and QA/AC analysts who work with USP monographs for pharmaceuticals and nutraceuticals. Participants may register online at http://www.usp.org/goto/usp621.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE